Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Endometriosis
Interventions: Naltrexone, Norethindrone Acetate, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Brain Death, Anoxic Brain Injury, Cardiac Arrest, Sedative Intoxication, Narcotic Intoxication
Interventions: Flumazenil, Naloxone; Drug
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
Interventions: Morphine PRN, Morphine scheduled; Drug
Lead sponsor: Indiana University; Other
Eligibility: Up to 28 Days
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pain, Fracture, Sprain
Interventions: Fentanyl, Lansoprazole, Oxycodone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: PF614, Oxycodone extended-release, Naltrexone Hydrochloride; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Opioid-Dependence Among Adolescents
Interventions: buprenorphine, naltrexone, behavior therapy, voucher-based contingency management; Drug · Procedure
Lead sponsor: National Development and Research Institutes, Inc.; Other
Eligibility: 13 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1993
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid Use
Interventions: Buprenorphine/Naloxone, Treatment as usual; Drug · Other
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hip Arthroscopy
Interventions: Hip Capsule Repair; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2040
U.S. locations: 3
States / cities: Scottsdale, Arizona • Westmont, Illinois • Rochester, Minnesota

Conditions: Heart Arrest, Out-Of-Hospital, Opioid Overdose, Naloxone
Interventions: Naloxone 2 MG, Saline 2ml; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid Dependence
Interventions: Brixadi, Vivitrol; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Pain
Interventions: Oxymorphone ER; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 13
States / cities: Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more

Conditions: Pain, Postoperative, Postoperative Nausea and Vomiting, Scoliosis
Interventions: Naloxone; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 10 Years to 21 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pain, Hernia
Interventions: Ibuprofen, Opioid Medication, Placebo, Ibuprofen + Opioid medication; Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Postoperative Ileus
Interventions: bupivacaine with hydromorphone, lidocaine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Opioid-Related Disorders, NAS, Substance Use Disorders, Mental Health
Interventions: Observational Study; Other
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 2,510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Augusta, Maine • Bangor, Maine • Keene, New Hampshire + 6 more

Conditions: Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission, Status Post Methadone-Maintenance Treatment
Interventions: Quetiapine; Drug
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use Disorder, Opioid Overdose
Interventions: a bundled intervention, including peer support specialist, buprenorphine, physician care, and telehealth; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 48 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Alzheimer Disease, Dementia, Dementia, Vascular, Pain
Interventions: hydrocodone/APAP w placebo PRN, hydrocodone/APAP, placebo with hydrocodone/APAP PRN; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Tuscaloosa, Alabama

Conditions: Sickle Cell Disease
Interventions: Morphine, Methadone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 7 Years to 40 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Interventions: Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring; Drug · Device · Behavioral + 1 more
Lead sponsor: Clive Michelsen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Basalt, Colorado

Conditions: Healthy
Interventions: Naloxone, Delta-9-THC, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: West Haven, Connecticut

Search by objective public record fields.

Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis

Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

Science-Based Treatment for Opioid-Dependent Adolescents

Buprenorphine Maintenance for Opiate Dependence - 6

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

CREST: Capsular Repair During Hip Arthroscopy

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery

Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy

Effects of Intravenous Local Anesthetic on Bowel Function After Colectomy

MOms in REcovery (MORE) Study: Defining Optimal Care

Anxiety in Recovering Opiate Dependence

A Bundled Intervention

Alternate-Day Buprenorphine Administration. Phase VII - 8

Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)

Methadone in Pediatric and Adult Sickle Cell Patients

Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder

The Effects of ∆-9-THC and Naloxone in Humans